ONC-841

DRUG2 trials

Sponsors

OncoC4, Inc.

Conditions

Advanced Solid Tumor

Phase 1

Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

WithdrawnNCT06219499

OncoC4, Inc.Advanced Solid Tumor

Start: 2024-06-30End: 2026-06-30Updated: 2024-04-03

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

RecruitingNCT06352359

OncoC4, Inc.Advanced Solid Tumor

Start: 2024-08-23End: 2027-09-30Target: 72Updated: 2026-06-25